Literature Highlights

Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.

Merrill et al. investigated the efficacy and safety of upadacitinib, elsubrutinib, and ABBV-599 in adults with moderately to severely active SLE. SRI-4, BICLA, and LLDAS response rates were higher for both upadacitinib and ABBV-599 high dose versus placebo at Weeks 24 and 48. Incidence of serious TEAEs through Week 48 was lower with ABBV-599 high dose than with upadacitinib 30mg or placebo. ABBV-599 low dose (elsubrutinib 60 mg QD + upadacitinib 15 mg) and elsubrutinib groups were discontinued due to lack of efficacy.